SEquential Treatment of PSoriasis With Biologics

NCT07187817 | Recruiting

• 1 other identifier: 001_F_23
• Study Type: observational
• Target: 366
• Locations: 1 country
• Sites: 1

Brief Summary

Psoriasis is a common skin condition that leads to patches of scaled skin which can be inflamed, sore and itchy. It can affect any area of skin on the body, as well as nails, and can be widespread and severe. Over the past 20 years, many new treatments have been developed and approved for severe psoriasis. Most of these newer treatments are given by injection and, as a group, are known as biologics. Many people respond well to biologics and have a meaningful improvement in their condition. There is a smaller proportion of people who do not respond well, or develop side effects, and so must switch drugs to try and improve their condition. In some cases, people need multiple lines of biologic treatment. Currently very little is understood about how well people respond when they are treated with three or more biologics in a row, as very few trials have been done in these cases. This study aims to use data from people who have already been treated with biologics by their Dermatology teams in the NHS and use the information obtained during their normal clinic appointments to investigate this question. The investigators will assess how well people respond to each line of biologic drug (1st to 10th). They will look at whether people respond as well or less well over time, the more biologics they have. People can be included in the research if they are 18 or over and have been treated with a biologic for psoriasis in participating hospitals in the NHS in England. In this study the investigators are assessing data from events that have previously happened, and so no extra visits are required

Conditions

Psoriasis

Keywords

biologic; bdmard; tsdmard; biological agent; 3rd line; 4th line; switch; cycle

Outcome Measures

Primary Outcomes (1)

• PASI75

  75% improvement in Psoriasis Area and Severity Index (PASI)

  12-16 weeks and 6 months

Secondary Outcomes (3)

• PASI90

  12-16 weeks and 6 months

• PASI100

  12-16 weeks and 6 months

• PASI<2

  12-16 weeks and 6 months

Study Arms (2)

2nd Line Biologic

Participants previously treated with 2 lines of biologic or targeted synthetic treatment for psoriasis.

3rd+ Line Biologic

Participants previously treated with 3 or more lines of biologic or targeted synthetic treatment for psoriasis.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants taken from population who have been treated with biologics and targeted synthetic treatments in Dermatology departments at participating NHS sites.

You may qualify if:

• Diagnosis of chronic plaque psoriasis by a Dermatology consultant
• Prior treatment with biologic or targeted synthetic treatment (1 to 10 lines) for psoriasis in the United Kingdom

You may not qualify if:

• Diagnosis of other forms of psoriasis for example generalised pustular psoriasis

Sponsors & Collaborators

• Royal United Hospitals Bath NHS Foundation Trust: lead
• University of Bath: collaborator
• University of Leeds: collaborator

Study Sites (1)

Royal United Hospitals Bath NHS Foundation Trust

Bath, Somerset, BA1 3NG, United Kingdom

RECRUITING

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Charlotte Gollins

CONTACT

01225 826192; charlotteelizabeth.gollins@nhs.net

Sarah Stratton

CONTACT

01225 826192; sarah.stratton@nhs.net

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 16, 2025
• First Posted: September 23, 2025
• Study Start: October 14, 2025
• Primary Completion: May 5, 2026
• Study Completion: May 5, 2026
• Last Updated: February 13, 2026

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)